

DAFTAR PUSTAKA

1. World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections. Geneva: WHO; 2017. 1–88 p.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States [Internet]. Centers for Disease Control and Prevention. 2019. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html
3. ECDC. Surveillance of antimicrobial resistance in Europe 2018. European Centre for Disease Prevention and Control. Stockholm; 2019.
4. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum β -lactamases. Vol. 6, Expert Review of Anti-Infective Therapy. Expert Reviews Ltd.; 2008. p. 671–83.
5. Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, et al. Comparison of Predictors and Mortality between Bloodstream Infections Caused by ESBL-Producing *Escherichia coli* and ESBL-Producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol* [Internet]. 2018 Jun 1 [cited 2020 Jul 4];39(6):660–7. Available from: </core/journals/infection-control-and-hospital-epidemiology/article/comparison-of-predictors-and-mortality-between-bloodstream-infections-caused-by-esblproducing-escherichia-coli-and-esblproducing-klebsiella-pneumoniae/989723D4DB614A6E4A3003EC46982744>
6. Hamzaoui Z, Ocampo-Sosa A, Fernandez Martinez M, Landolsi S, Ferjani S, Maamar E, et al. Role of association of OmpK35 and OmpK36 alteration and bla ESBL and/or bla AmpC genes in conferring carbapenem resistance among non-carbapenemase-producing *Klebsiella pneumoniae* [Internet]. Vol. 52, International Journal of Antimicrobial Agents. Elsevier B.V.; 2018. 898–905 p.

Available from: <https://doi.org/10.1016/j.ijantimicag.2018.03.020>

7. Wyres KL, Holt KE. *Klebsiella pneumoniae* as a key trafficker of drug resistance genes from environmental to clinically important bacteria. *Curr Opin Microbiol* [Internet]. 2018 Oct [cited 2019 Mar 23];45:131–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1369527418300225>
8. Giske CG, Martinez-Martinez L, Cantón Spain R, Stefani S, Skov R, Glupczynski Y, et al. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. *Eur Comm Antimicrob Susceptibility Test* [Internet]. 2017;1–43. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf
9. Grimont PAD, Grimont F. *Klebsiella*. *Bergey's Man Syst Archaea Bact*. 2015;1–26.
10. Riedel S, Hobden JA, Miller S. Jawetz, Melnick and Adelberg's *Medical Microbiology: 28th Edition*. Jawetz, Melnick & Adelberg's *Medical Microbiology*. 2019. 746–747 p.
11. Paczosa MK, Meccas J. *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev*. 2016;80(3):629–61.
12. Walsh C, Wencemicz T. *Antibiotics: Challenges, Mechanisms, Opportunities*. Vol. 14, *Marine Drugs*. 2016. 1–2 p.
13. Carattoli A. Plasmids and the spread of resistance. *Int J Med Microbiol* [Internet]. 2013;303(6–7):298–304. Available from: <http://dx.doi.org/10.1016/j.ijmm.2013.02.001>
14. Bush K, Jacoby GA. Updated functional classification of β -lactamases. *Antimicrob Agents Chemother*. 2010;54(3):969–76.

15. Paterson DL, Bonomo RA. Clinical Update Extended-Spectrum Beta-Lactamases : a Clinical Update. *Clin Microbiol Rev* [Internet]. 2005;18(4):657–86. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1265908/>
16. Bradford P. Extended Spectrum B-Lactamases in the 21st Century: Characterization, Epidemiology and Detection of this Important Resistance Threat. *Clin Microbiol Rev*. 2001;14(4):933–51.
17. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL - producing Enterobacteriaceae in Europe. *Euro Surveill* [Internet]. 2008;13(47):1–11. Available from: www.eurosurveillance.org
18. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018;18(3).
19. McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, et al. Incidence of extended-spectrum β -Lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella* infections in the United States: A systematic literature review. *Infect Control Hosp Epidemiol* [Internet]. 2017 Oct 1 [cited 2020 Jul 4];38(10):1209–15. Available from: [/core/journals/infection-control-and-hospital-epidemiology/article/incidence-of-extended-spectrum-lactamase-esbl-producing-escherichia-coli-and-klebsiella-infections-in-the-united-states-a-systematic-literature-review/25AE94CD8F01BEDEC7C73306FE46BA69](https://doi.org/10.1017/S0950268817000000)
20. Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. *J Chemother* [Internet]. 2017;29:2–9. Available from: <https://doi.org/10.1080/1120009X.2017.1380395>
21. Severin JA, Mertaniasih NM, Kuntaman K, Lestari ES, Purwanta M, Lemmens-Den Toom N, et al. Molecular characterization of extended-spectrum β -lactamases in clinical *Escherichia coli* and

- Klebsiella pneumoniae* isolates from Surabaya, Indonesia. *J Antimicrob Chemother.* 2010;65(3):465–9.
22. Flokas ME, Karanika S, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: A systematic review and meta-analysis. *PLoS One.* 2017;12(1):1–13.
 23. Liao K, Chen Y, Wang M, Guo P, Yang Q, Ni Y, et al. Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* causing intra-abdominal infections from 9 tertiary hospitals in China. *Diagn Microbiol Infect Dis.* 2017 Jan 1;87(1):45–8.
 24. Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. *Biomed Res Int.* 2018;2018.
 25. Naelasari DN, Koendhori EB, Dewanti L, Sarassari R, Kuntaman K, Airlangga U. THE PREVALENCE OF EXTENDED SPECTRUM β -LACTAMASE (ESBL) PRODUCING GUT BACTERIAL FLORA AMONG PATIENTS IN DR . SOETOMO HOSPITAL AND PRIMARY. 2018;54(4):256–62.
 26. Diagbouga S, Yao Sadjji A, ouaga pr Joseph ki-Zerbo universit  I, D SF, Y SA, M DA, et al. Detection of High Prevalence of TEM/SHV/CTX-M Genes in ESBL Producing and Multidrug Resistant *Klebsiella pneumoniae* and *Klebsiella oxytoca* Amana Metuor Dabire Detection of High Prevalence of TEM/SHV/CTX-M Genes in ESBL Producing and Multidrug Resistant *Klebsiella pneumoniae* and *Klebsiella oxytoca*. 2016 [cited 2020 Jul 4]; Available from: <https://www.researchgate.net/publication/316664792>
 27. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol*

- Infect [Internet]. 2012;18(3):268–81. Available from:
<http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x>
28. Nijssen S, Florijn A, Bonten M, ... FS-I journal of, 2004 undefined. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Elsevier [Internet]. [cited 2020 Jul 3]; Available from: <https://www.sciencedirect.com/science/article/pii/S0924857904003358>
 29. Farida H, Severin JA, Gasem MH, Keuter M, Van Den Broek P, Hermans PWM, et al. Nasopharyngeal Carriage of *Klebsiella pneumoniae* and Other Gram-Negative Bacilli in Pneumonia-Prone Age Groups in Semarang, Indonesia Downloaded from. 1614 jcm.asm.org J Clin Microbiol [Internet]. 2013 [cited 2020 Jun 28];51:1614–6. Available from: <http://jcm.asm.org/>
 30. Severin JA, Lestari ES, Kloezen W, Lemmens-den Toom N, Mertaniasih NM, Kuntaman K, et al. Faecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001-2002. Trop Med Int Heal. 2012 Apr 1;17(4):455–61.
 31. Hamid F, Munawir M, Sultan AR, Bramantyas KH, Amaruddin I. Prevalence of Fecal Carriage of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae Among School Children in South Sulawesi, Indonesia. Arch Clin Infect Dis. 2020;15(2).
 32. Surgers L, Boyd A, Girard PM, Arlet G, Decré D. Biofilm formation by ESBL-producing strains of *Escherichia coli* and *Klebsiella pneumoniae*. Int J Med Microbiol [Internet]. 2019;309(1):13–8. Available from: <https://doi.org/10.1016/j.ijmm.2018.10.008>
 33. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJGT. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev

- Microbiol. 2016;42(1):1–16.
34. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. *Infect Control Hosp Epidemiol.* 2016;37(11):1288–301.
 35. Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organi. *J Infect.* 2015;70(3):213–22.
 36. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front Microbiol.* 2019;10(APR).
 37. Rupp M, Fey PD, Rupp ME, Fey PD. Extended spectrum β -lactamase (ESBL) - producing Enterobacteriaceae : Considerations for ... Extended Spectrum β -Lactamase (ESBL) -Producing Enterobacteriaceae. *Drugs.* 2003;63(February):353–65.
 38. Sawa T, Kooguchi K, Moriyama K. Molecular diversity of extended-spectrum β -lactamases and carbapenemases, and antimicrobial resistance. *J Intensive Care.* 2020;8(1):1–13.
 39. Scott B&. *General Principles in Clinical Microbiology. Diagnostic Microbiology.* 2014. 153–166 p.
 40. EUCAST. Testing Breakpoint tables for interpretation of MICs and zone diameters. https://WwwEucastOrg/Ast_of_Bacteria/ [Internet]. 2020;0–77. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf

41. Poulou A, Grivakou E, Vrioni G, Koumaki V, Pittaras T, Pournaras S, et al. Modified CLSI Extended-Spectrum-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various-Lactamases. 2014;
42. Clinical Laboratory Standards Institute. CLSI M100-ED29 : 2019 Performance Standards for Antimicrobial Susceptibility Testing , 29th Edition. CLSI. 2019. 100–102 p.
43. Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, et al. Clinical Risk Score for Prediction of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. *Infect Control Hosp Epidemiol*. 2017;38(3):266–72.
44. Gorrie CL, Mirceta M, Wick RR, Judd LM, Wyres KL, Thomson NR, et al. Antimicrobial-resistant klebsiella pneumoniae carriage and infection in specialized geriatric care wards linked to acquisition in the referring hospital. *Clin Infect Dis*. 2018;67(2):161–70.
45. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis*. 2017 Feb 1;17(2):153–63.
46. M S, U. S. Extended spectrum beta lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *J Assoc Physicians India*. 2010;58(41).
47. Gharrah MM, Mostafa El-Mahdy A, Fathy Barwa R. Association between Virulence Factors and Extended Spectrum Beta-Lactamase Producing *Klebsiella pneumoniae* Compared to Nonproducing Isolates. *Interdiscip Infect Dis [Internet]*. 2017 [cited 2019 Aug 12]; Available from: <https://doi.org/10.1155/2017/7279830>

48. Sader HS, Castanheira M, Arends SJR, Goossens H, Flamm RK. Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016). *J Antimicrob Chemother* [Internet]. 2019 Jun 1;74(6):1595–606. Available from: <https://doi.org/10.1093/jac/dkz074>
49. Parathon H, Kuntaman K. Progress towards antimicrobial resistance containment and control in Indonesia. *BMJ* [Internet]. Available from: <http://www.bmj.com/>
50. Winarto. Prevalensi Kuman ESBL (Extended Spectrum Beta Lactamase) dari Material Darah di RSUP Dr. Kariadi Tahun 2004-2005. *Media Med Indones*. 2009;43(5).
51. Sinanjung K, Aman AT, Nirwati H. Extended spectrum beta lactamase (ESBL) -producing *Klebsiella pneumoniae* clinical isolates and its susceptibility pattern to antibiotics at Dr . Soeradji Tirtonegoro General Hospital Klaten , Central Java. 2020;52(1):17–27.
52. Willemsen I, Oome S, Verhulst C, ... AP-PI, 2015 undefined. Trends in extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae and ESBL genes in a Dutch teaching hospital, measured in 5 yearly point. *journals.plos.org* [Internet]. [cited 2020 Jul 3]; Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141765>
53. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat Rev Microbiol* [Internet]. 2020;18(6):344–59. Available from: <http://dx.doi.org/10.1038/s41579-019-0315-1>
54. Nengah N, Fatmawati D, Made N, Tarini A, Nyoman N, Budayanti S, et al. Molecular Characterization of Extended-Spectrum-Lactamases-Producing *Lebsiellapneumoniae* Isolated from Clinical

Specimens at a Tertiary-Referral Hospital in Denpasar, Bali,
Indonesia. Adv Sci Lett [Internet]. 2015 [cited 2020 Jun 28];21:219–
21. Available from:
<https://www.ingentaconnect.com/content/asp/asl/2015/00000021/0000002/art00025>

LAMPIRAN

